{"url_path":"/sec/pavm/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and Procedures**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1624326/0001437749-26-017121-index.html","accession_number":"0001437749-26-017121","cik":"0001624326","ticker":"PAVM","issuer_name":"PAVmed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1624326/0001437749-26-017121-index.html","primary_entity_key":"0001624326","primary_entity_name":"PAVmed Inc."},"word_count":236,"has_tables":true,"body_markdown":"**Item 4. Controls and Procedures**\n\n \n\n**Evaluation of Disclosure Controls and Procedures**\n\n \n\nOur management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. Based on such evaluation, our principal executive officer and principal financial officer concluded our disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) were effective as of such date to provide reasonable assurance the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.\n\n \n\n**Changes to Internal Controls Over Financial Reporting**\n\n \n\nThere has been no change in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fiscal quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.\n\n \n\n41\n\n[Table of Contents](#toc)\n\n \n\n \n\n**Part II - Other Information**"}